何去何从?对17-α羟孕酮己酸酯预防复发性早产20余年临床与研究经验的批判性评估
本文汇总美国2003至2023年间使用17-α羟孕酮己酸酯预防复发性早产的临床与研究数据,涉及用药历史、作用机制、临床试验结果及按临床与生物学标准的疗效。作者指出设计严谨的研究结论不一可能反映先验风险与人群发病率差异,解读研究时需格外谨慎。
要点
- 近期一项确证性试验结果为阴性后,17-α羟孕酮己酸酯已退出美国市场,目前仅可通过临床研究获取。
- 设计相似的研究结论不一,可能反映先验风险与人群发病率的差异。
- 改善产科结局的可能性可能因体重指数、血浆药物浓度和遗传因素而异。
核心结论
- 设计严谨但结论不一的研究可能反映先验风险与人群发病率差异,解读疗效时应格外谨慎。
- 接受17-α羟孕酮己酸酯后产科结局改善的可能性可能因临床因素(如体重指数)、血浆药物浓度和遗传因素而异。
研究设计与样本
- 专家综述,汇总美国2003年至2023年间关于17-α羟孕酮己酸酯用于复发性早产预防的临床与研究数据。
主要发现
- 近期一项确证性试验结果为阴性后,17-α羟孕酮己酸酯退出美国市场,目前仅可通过临床研究获取。
- 识别最可能获益的个体仍不完善。
- 设计严谨的研究之间结论不一,可能反映先验风险与人群发病率的差异。
关键数值与推荐
- 改善产科结局的可能性可能因体重指数等临床因素、血浆药物浓度和遗传因素而异。
临床怎么用
- 作者认为医学界应认识到保留美国数十年来在预防复发性早产方面投入的重要性。
- 作者认为应全面审慎地评估17-α羟孕酮己酸酯,将其视为未来实施良好的早产研究的有前景候选药物。
局限性
- 识别最可能获益的个体仍不完善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spontaneous preterm birth is multifactorial, and underlying etiologies remain incompletely understood. Supplementation with progestogens, including 17-alpha hydroxyprogesterone caproate has been a mainstay of prematurity prevention strategies in the United States in the last 2 decades. Following a recent negative confirmatory trial, 17-alpha hydroxyprogesterone caproate was withdrawn from the US market and is currently available only through clinical research studies. This expert review summarized clinical and research data regarding the use of 17-alpha hydroxyprogesterone caproate in the United States from 2003 to 2023 for recurrent prematurity prevention. In 17-alpha hydroxyprogesterone caproate. The history of the use, mechanisms of action, clinical trial results, and efficacy by clinical and biologic criteria of 17-alpha hydroxyprogesterone caproate are presented. We report that disparate findings and conclusions between similarly designed rigorous studies may reflect differences in a priori risk and population incidence and extreme care should be taken in interpreting the studies and making decisions regarding efficacy of 17-alpha hydroxyprogesterone caproate for the prevention of preterm birth. The likelihood of improved obstetrical outcomes after receiving 17-alpha hydroxyprogesterone caproate may vary by clinical factors (eg, body mass index), plasma drug concentrations, and genetic factors, although the identification of individuals most likely to benefit remains imperfect. It is crucial for the medical community to recognize the importance of preserving the decades-long efforts invested in preventing recurrent preterm birth in the United States. Moreover, it is important that we thoroughly and thoughtfully evaluate 17-alpha hydroxyprogesterone caproate as a promising contender for future well-executed prematurity studies.
引用
- Manuck TA, Gyamfi-Bannerman C, Saade G, et al. What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol MFM. 2023. PMID: 37527737. doi:10.1016/j.ajogmf.2023.101108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。